Mean plasmatic VEGFA concentration (Figure 3) was significantly increased in plasma from FD patients compared to healthy controls (2.97 ± 0.79 pg/mL in controls and 8.63 ± 1.83 pg/mL in FD patients: in naïve 6.64 ± 2.47 pg/mL and in ERT-treated 10.42 ± 2.56 pg/mL), and the difference was also significant when comparing the male FD patient group with male healthy controls. Here, VEGFA is linked to Fabry disease.